Actinium Pharmaceuticals Inc (ATNM)

$1.46 +0.03 (2.10%)
Market Cap 42.74M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 68,400
Avg Vol 198,366
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 46%
Beta -0.30
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Pinto72
Pinto72 Jan. 8 at 5:47 AM
$ATNM Sounds like an ATNM pumper! ROUGE 🤣🤣🤣🤣🤣 and WHERE🚀🚀🚀🚀🚀🚀 HELLOOOOOO, DOGGIE!!!!!! BANKRUPTCY = AS SOON!!!!!! eXtReEmLeE bUlLiSh!!!!! 📉📉📉📉📉📉
1 · Reply
Pinto72
Pinto72 Jan. 8 at 5:36 AM
$ATNM It’s quite obvious @johnny4skin ate crayons and licked windows as a young child. He may have continued that trend into his 70’s? Not judging…….. eXtReEmLeE bUlLiSh!!! 🤣🤣🤣🤣🤣
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:20 AM
$ATNM ai cont
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:18 AM
$ATNM from ai
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:02 AM
$ATNM
0 · Reply
Pinto72
Pinto72 Jan. 7 at 8:54 PM
$ATNM Niche therapies for minuscule patient populations. Also the FACT this is a complete SCAM! HELLOOOOOOOOO, AAVIE!!!!!!! BANKRUPTCY = AS SOON🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!! 🤣🤣🤣🤣🤣
0 · Reply
resume777
resume777 Jan. 7 at 12:29 PM
$ATNM https://oilprice.com/Alternative-Energy/Nuclear-Power/Washington-Commits-27-Billion-to-Break-Russias-Grip-on-Nuclear-Fuel.html The Department of Energy will award $2.7 billion over 10 years to three firms to expand U.S. uranium enrichment. This includes an investment in a centrifuge manufacturing facility in Oak Ridge, Tennessee, to support the growth and reduce reliance on foreign supply chains.
0 · Reply
itsverified
itsverified Jan. 6 at 8:40 PM
$CVM $UPC $ATNM $CAPR $ALMS Cel-sci is on watch for a breakout of its downward trend with FDA confirmatory trail enrollment starting Q1 26 and expecting Breakthrough Medicine Designation from SFDA any day now.
2 · Reply
johnny4cures
johnny4cures Jan. 6 at 8:32 PM
$ATNM Looking forward to udates on ATNM-400 and ACTIMAB-A in solid cancer tumors cancer. One example: https://ir.actiniumpharma.com/press-releases/detail/513/actinium-pharmaceuticals-presents-new-preclinical-data
1 · Reply
johnny4cures
johnny4cures Jan. 6 at 8:28 PM
$ATNM https://www.newyorker.com/culture/the-weekend-essay/a-battle-with-my-blood Good read This is the plight of the Relapsed and Refractory AML patient and good reaso to get Iomab-B to approval. Although the company has moved on to the most common 3 types of cancer such as Pca, Lca, and Bca there is still an unmet need with RR-AML.
0 · Reply
Latest News on ATNM
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Dec 12, 2025, 8:45 AM EST - 26 days ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec 1, 2025, 8:45 AM EST - 5 weeks ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov 17, 2025, 8:30 AM EST - 7 weeks ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 2 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 3 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 3 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 5 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 7 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 8 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 9 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 9 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 9 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 9 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 9 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Pinto72
Pinto72 Jan. 8 at 5:47 AM
$ATNM Sounds like an ATNM pumper! ROUGE 🤣🤣🤣🤣🤣 and WHERE🚀🚀🚀🚀🚀🚀 HELLOOOOOO, DOGGIE!!!!!! BANKRUPTCY = AS SOON!!!!!! eXtReEmLeE bUlLiSh!!!!! 📉📉📉📉📉📉
1 · Reply
Pinto72
Pinto72 Jan. 8 at 5:36 AM
$ATNM It’s quite obvious @johnny4skin ate crayons and licked windows as a young child. He may have continued that trend into his 70’s? Not judging…….. eXtReEmLeE bUlLiSh!!! 🤣🤣🤣🤣🤣
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:20 AM
$ATNM ai cont
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:18 AM
$ATNM from ai
0 · Reply
johnny4cures
johnny4cures Jan. 8 at 2:02 AM
$ATNM
0 · Reply
Pinto72
Pinto72 Jan. 7 at 8:54 PM
$ATNM Niche therapies for minuscule patient populations. Also the FACT this is a complete SCAM! HELLOOOOOOOOO, AAVIE!!!!!!! BANKRUPTCY = AS SOON🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!! 🤣🤣🤣🤣🤣
0 · Reply
resume777
resume777 Jan. 7 at 12:29 PM
$ATNM https://oilprice.com/Alternative-Energy/Nuclear-Power/Washington-Commits-27-Billion-to-Break-Russias-Grip-on-Nuclear-Fuel.html The Department of Energy will award $2.7 billion over 10 years to three firms to expand U.S. uranium enrichment. This includes an investment in a centrifuge manufacturing facility in Oak Ridge, Tennessee, to support the growth and reduce reliance on foreign supply chains.
0 · Reply
itsverified
itsverified Jan. 6 at 8:40 PM
$CVM $UPC $ATNM $CAPR $ALMS Cel-sci is on watch for a breakout of its downward trend with FDA confirmatory trail enrollment starting Q1 26 and expecting Breakthrough Medicine Designation from SFDA any day now.
2 · Reply
johnny4cures
johnny4cures Jan. 6 at 8:32 PM
$ATNM Looking forward to udates on ATNM-400 and ACTIMAB-A in solid cancer tumors cancer. One example: https://ir.actiniumpharma.com/press-releases/detail/513/actinium-pharmaceuticals-presents-new-preclinical-data
1 · Reply
johnny4cures
johnny4cures Jan. 6 at 8:28 PM
$ATNM https://www.newyorker.com/culture/the-weekend-essay/a-battle-with-my-blood Good read This is the plight of the Relapsed and Refractory AML patient and good reaso to get Iomab-B to approval. Although the company has moved on to the most common 3 types of cancer such as Pca, Lca, and Bca there is still an unmet need with RR-AML.
0 · Reply
tjm1
tjm1 Jan. 6 at 7:37 PM
$ATNM How does the FDA allow new treatments go to market and on the tv commercials introducing the "breakthrough" treatments they clearly recommend to check with your doctor as this breakthrough could result in headaches, nausea, heart complications or death BUT they wouldn't allow ATNM go to market with the same warnings.
0 · Reply
resume777
resume777 Jan. 6 at 12:13 PM
$ATNM Study Start (Estimated) 2026-01 https://www.clinicaltrials.gov/study/NCT07157514?term=Apamistamab&viewType=Card&rank=3 While AC225 is under drug supply issues and ATNM-400 is preclinical, $ATNM needs to get their Phase 2/3 131I- Apamistamab trial underway. Same for providing an update on the IOMAB-ACT study. For now, it doesn't look like it'll be at the 2026 Tandem Meetings in Salt Lake, UT. https://www.clinicaltrials.gov/study/NCT06768905?term=Apamistamab&viewType=Card&rank=4
2 · Reply
itsverified
itsverified Jan. 6 at 2:07 AM
$ATNM up 25% since my post last week. Don’t miss this one
0 · Reply
SageSpirits
SageSpirits Jan. 5 at 10:52 PM
$ATNM umm. yeah. happy new year. does this thing have a chance? Have we ATNMers for all practical purposes, started all over from scratch? Starting a backyard Nursery business this year featuring Niche herbs and medicinal plants as well as the typical grocery store items. Looking to attract the apothecary gardener as well as the typical. I thought I was going to go in the "market gardener" direction but as I discovered this year, I have no where near enough space. Better to educate people on doing their own gardening and selling them quality plants. Uncertainty is in the air...
0 · Reply
Jimmy1940
Jimmy1940 Jan. 5 at 6:05 PM
$ATNM where did all of our money go ?
1 · Reply
Pinto72
Pinto72 Jan. 5 at 5:59 PM
$ATNM HELLOOOOOOO, RICHIII!!!! BANKRUPTCY = AS SOON🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh🤣🤣🤣🤣🤣
0 · Reply
Arneyjivers
Arneyjivers Jan. 5 at 3:15 PM
$ATNM nice to see good doggies still posting relevant information. Possibly that's the reason the stock is in the tank.
0 · Reply
gooddoggie
gooddoggie Jan. 4 at 11:07 PM
$ATNM Well that’s just great. Now the Amazons send emails “we saw you looking”! Hey! Stop watching me! Now I open Amazon and see 300 blow up dolls. And they aren’t all ladies!
0 · Reply
luzongeezer
luzongeezer Jan. 4 at 1:56 PM
$ATNM Tiger got to hunt Bird got to fly Man got to ask himself Why, why, why. Tiger got to eat Bird got to land Man got to tell himself He understand. --Kurt Vonnegut, Jr.
4 · Reply
gooddoggie
gooddoggie Jan. 3 at 9:19 PM
$ATNM Seth had a “strong presence” at ASH 2018. Then they told him about the wonder of deodorant.
0 · Reply
gooddoggie
gooddoggie Jan. 3 at 6:08 AM
$ATNM The obvious solution here is to eat vegetables while having sex.
2 · Reply
alcacer123
alcacer123 Jan. 2 at 6:43 PM
$ATNM Seth, when are you starting to market AC225? This is going to be monumental.
1 · Reply